Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 10/20 | 1.00 |
| ▸ | HTR3A | P46098 | 4/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | HTR5A | P47898 | 1/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norcisapride SCHEMBL593405 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Norcisapride SCHEMBL3319911 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Norcisapride SCHEMBL8245159 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Norcisapride SCHEMBL3317329 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Norcisapride SCHEMBL734363 | 1.00 | HTR4 (1.00) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| SCHEMBL9790000 | 0.96 | HTR4 (0.92) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| SCHEMBL9789990 | 0.96 | HTR4 (0.92) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| SCHEMBL9789995 | 0.96 | HTR4 (0.92) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Ticalopride SCHEMBL6847230 | 0.92 | HTR4 (0.85) | HTR4HTR3AHTR3EHTR3BHTR5A | |
| Water SCHEMBL9721747 | 0.89 | HTR4 (0.80) | HTR4HTR3AHTR3EHTR3BHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1002 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| US-20160184387-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | CHARMOT DOMINIQUE (US) | 2016-06-30 | — | — | US | claimed |
| EP-3030252-A2 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | Ardelyx, Inc. (US) | 2016-06-15 | — | — | EP | claimed |
| CN-105636438-A | Pharmaceutical composition comprising an AMPK activator and a serotonin active agent and uses thereof | CHEN JIANHONG | 2016-06-01 | — | — | CN | claimed |
| EP-1682098-B1 | COLONIC PURGATIVE COMPOSITION WITH SOLUBLE BINDING AGENT | SALIX PHARMACEUTICALS INC (US) | 2016-05-25 | — | — | EP | claimed |
| EP-2983473-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS Mountain Llc (US) | 2016-02-17 | — | — | EP | claimed |
| US-9173953-B2 | Prodrugs containing an aromatic amine connected by an amido bond to a linker | ASCENDIS PHARMA AS (DK) | 2015-11-03 | — | — | US | claimed |
| CN-104936581-A | Laxative compositions and methods for treating constipation and related gastrointestinal disorders and conditions | SALIX PHARMACEUTICALS INC | 2015-09-23 | — | — | CN | claimed |
| EP-2890367-A1 | LAXATIVE COMPOSITIONS AND METHODS FOR TREATING CONSTIPATION AND RELATED GASTROINTESTINAL DISEASES AND CONDITIONS | Salix Pharmaceuticals, Inc. (US) | 2015-07-08 | — | — | EP | claimed |
| CN-1215992-A | Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride | SEPRACOR INC (US) | 1999-05-05 | — | — | CN | claimed |
| US-5877188-A | PSYCHOLOGICAL AND BEHAVIORAL DISORDERS, ANTIEMETICS | SEPRACOR INC. (US) | 1999-03-02 | — | — | US | claimed |
| US-5877189-A | PURE ISOMER | SEPRACOR INC. (US) | 1999-03-02 | — | — | US | claimed |
| EP-0896539-A1 | METHODS FOR TREATING EMESIS AND CENTRAL NERVOUS SYSTEM DISORDERS USING OPTICALLY PURE (+) NORCISAPRIDE | SEPRACOR, INC. (US) | 1999-02-17 | — | — | EP | claimed |
| US-5739151-A | TREATING GASTROINTESTINAL DISORDER WITH EMETIC AGENTS | SEPRACOR INC. (US) | 1998-04-14 | — | — | US | claimed |
| EP-0831821-A1 | OPTICALLY PURE (-) NORCISAPRIDE FOR TREATING DIGESTIVE TRACT DISORDERS | SEPRACOR, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1998003173-A1 | METHODS FOR TREATING EMESIS AND CENTRAL NERVOUS SYSTEM DISORDERS USING OPTICALLY PURE (+) NORCISAPRIDE | SEPRACOR INC. (US) | 1998-01-29 | — | — | WO | claimed |
| US-5712293-A | GASTROINTESTINAL DISORDERS | SEPRACOR, INC. (US) | 1998-01-27 | — | — | US | claimed |
| WO-1996040133-A1 | OPTICALLY PURE (-) NORCISAPRIDE FOR TREATING DIGESTIVE TRACT DISORDERS | SEPRACOR INC. (US) | 1996-12-19 | — | — | WO | claimed |
| US-5137896-A | Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184387-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | HTR4 1928/4885HTR3A 991/4885HTR3E 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.